# Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

> **NCT04216589** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 51 (actual)

## Conditions studied

- HIV Infections
- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04216589
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-19
- **Primary completion:** 2023-03-16
- **Final completion:** 2023-09-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216589, "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04216589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*